問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberCS8958-A-A202

2007-11-15 - 2008-06-30

Phase II

Terminated23

Study ended1

  • Trial Applicant

    PROTECH PHARMASERVICES CORPORATION

  • Sponsor

  • Trial scale

    Taiwan Multiple Center

  • Update

    2025/08/20

Investigators and Locations

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 陳志道 Division of Family Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 沈光漢 Division of Thoracic Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator Liang-wen Hang Division of Thoracic Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 彭萬誠 Division of Thoracic Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 陳建光 Division of Emergency Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 劉杜鎮 Division of Thoracic Medicine

Co-Principal Investigator

  • 蔡哲宏 Division of Emergency Medicine
  • 惠群 Division of Thoracic Medicine

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 王華恭 Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 劉建衛 Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator Yung-Ching Liu Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 陶啟偉 Division of Thoracic Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Study ended

Principal Investigator Yin-Ching Chuang Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator Wen-Sen Lee Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 陳昶華 Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 王立信 Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator Yu-Jiun Chan Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 曹世明 Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 劉有增 Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 盧進德 Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator Hsi-Hsun Lin Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 林明憲 Division of Thoracic Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    300 participants

  • Global

    300 participants